Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2011

Open Access 01-04-2011 | Original Article

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Authors: Yutaka Ueda, Takahito Miyake, Tomomi Egawa-Takata, Takashi Miyatake, Shinya Matsuzaki, Takuhei Yokoyama, Kiyoshi Yoshino, Masami Fujita, Takayuki Enomoto, Tadashi Kimura

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2011

Login to get access

Abstract

Purpose

A combined chemotherapy of taxane and platinum, with or without anthracycline, has been used as a standard first-line regimen. The purpose of this study was to investigate the effectiveness of second-line chemotherapy for treatment of advanced or recurrent endometrial carcinoma previously treated with a combined chemotherapy of taxane and platinum, with or without anthracycline.

Methods

During the 2000–2008 study period, 723 patients were diagnosed with endometrial cancer at the Departments of Obstetrics and Gynecology of the Osaka University and the Osaka Rosai Hospitals, Osaka, Japan. The subset of these cases that eventually required treatment by second-line chemotherapy was retrospectively analyzed.

Results

Response rate to second-line chemotherapy was 25%. Treatment-free interval (TFI) of ≥ or <6 months was demonstrated to be significantly associated with the response to second-line chemotherapy (P = 0.0026), progression-free survival (P = 0.0003) and overall survival (P = 0.025). The second-line chemotherapy similar to the first-line regimen was ineffective in all the 7 cases (100%) whose TFI was shorter than 6 months. Multivariate analysis showed that TFI was the most significantly important factor predicting the effectiveness of second-line chemotherapy (the adjusted hazard ratio of TFI on PFS and OS: 3.482, 95% CI, 1.641–7.388, P = 0.0012, and 2.341, 95% CI, 1.034–5.301, P = 0.042, respectively).

Conclusions

Our present study provides, for the first time, evidence that the majority of refractory or recurrent diseases, if they occur within 6 months of a first-line chemotherapy using taxane and platinum with or without anthracycline, are non-responsive to the current regimens of second-line chemotherapy.
Literature
1.
DiSaia PJ, Creasman WT (2002) Clinical gynecologic oncology, 6th edn. St. Louis, Mosby
2.
Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ (2000) Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78:85–91PubMedCrossRef
3.
Berek JS (2002) Novak’s Gynecology, 13th edn. William and Wilkins, Baltimore
4.
Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA (2006) Gynecologic oncology group study randomized phase iii trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 24:36–44PubMedCrossRef
5.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R (2008) Japanese gynecologic oncology group randomized phase iii trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate—and high risk endometrial cancer: a Japanese gynecologic oncology group study. Gynecol Oncol 108:226–233PubMedCrossRef
6.
Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, Ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB (2003) European organisation for research, treatment of cancer gynaecological cancer group. Doxorubicin versus doxorubicin, cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC gynaecological cancer group. Ann Oncol 14:441–448PubMedCrossRef
7.
Ball HG, Blessing JA, Lentz SS, Mutch DG (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol 62:278–281PubMedCrossRef
8.
Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159–2166PubMedCrossRef
9.
Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, Sessa C (1997) Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 8:969–972PubMedCrossRef
10.
Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, Barakat R, Chi DS, Sabbatini P, Spriggs DR, Aghajanian C (2006) Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol 103:451–457PubMedCrossRef
11.
Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA (2008) Hellenic co-operative oncology group. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic co-operative oncology group (HeCOG) study. Gynecol Oncol 110:87–92PubMedCrossRef
12.
Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19:4048–4053PubMed
13.
du Bois A, Neijt JP, Thigpen JT (1999) First-line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer–a new standard of care? Ann Oncol 10(Suppl 1):35–41PubMedCrossRef
14.
Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME (2003) Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 88:51–57PubMedCrossRef
15.
Kikuchi A, Sakamoto H, Yamamoto T (2005) Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. Int J Gynecol Cancer 15:45–49PubMedCrossRef
16.
World Health Organization (1979) WHO handbook of reporting results of cancer treatment no. 48. WHO Offset Publication, Geneva
17.
Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T (2008) Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 109:250–254PubMedCrossRef
18.
Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853–3858PubMedCrossRef
19.
Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y (2006) Prognostic significance of p53 mutation in sub optimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 241:289–300PubMedCrossRef
20.
Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120–3125PubMedCrossRef
21.
Harries M, Gore M (2002) Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 3:537–545PubMedCrossRef
22.
Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–653PubMedCrossRef
23.
Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207–211PubMedCrossRef
24.
Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W (1991) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801–1805PubMed
Metadata
Title
Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
Authors
Yutaka Ueda
Takahito Miyake
Tomomi Egawa-Takata
Takashi Miyatake
Shinya Matsuzaki
Takuhei Yokoyama
Kiyoshi Yoshino
Masami Fujita
Takayuki Enomoto
Tadashi Kimura
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1384-z

Other articles of this Issue 4/2011

Cancer Chemotherapy and Pharmacology 4/2011 Go to the issue

Original Article

2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion

Original Article

Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure

Original Article

Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract

Original Article

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer

Original Article

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Original Article

Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits